A Trial Investigating the Pharmacokinetic Properties of Fast-acting Insulin Aspart in Chinese Subjects With Type 1 Diabetes or Type 2 Diabetes
Latest Information Update: 28 Feb 2024
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 23 Feb 2024 Status changed from recruiting to completed.
- 07 Jul 2023 Planned End Date changed from 30 Nov 2023 to 30 Jan 2024.
- 07 Jul 2023 Planned primary completion date changed from 30 Nov 2023 to 9 Jan 2024.